Literature DB >> 26368553

Tailoring Treatment to the Individual Patient - Will Inflammatory Bowel Disease Medicine Be Personalized?

Claudio Fiocchi.   

Abstract

Personalized medicine is variably defined as a new system aimed at providing optimal medical care by using comprehensive pathophysiology-based information on all aspects and components of a disease process to prevent, diagnose and treat in ways that are custom-made for the individual patient. The need for personalized medicine derives from the realization that today's most challenging medical conditions are chronic complex diseases with multiple pathogenic components that interact with each other. Complexity and interaction together create unique molecular pathways that are only relevant to certain disease subtypes, but not to the entire population of patients with the same diagnosis. Thus, complex diseases cannot be properly controlled, and much less cured, by modulating single components at sporadic time points in the course of the disease or administering the same treatment to all patients, as we currently do in the management of inflammatory bowel disease (IBD). The implementation of personalized medicine requires entirely novel and methodologically sophisticated bioinformatics-based approaches that use comprehensive and detailed information on the various components ('omes') of the disease process. This requires identifying the key controllers ('hubs') of pathogenic pathways in a totally unbiased fashion and discovering highly specific agents that can selectively block or even revert pathogenic events. IBD is a perfect example of a condition with multiple causes and multiple mechanisms, and IBD patients will unquestionably benefit from the adoption of personalized medicine in the near future.
© 2015 S. Karger AG, Basel.

Entities:  

Year:  2015        PMID: 26368553     DOI: 10.1159/000437086

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  3 in total

Review 1.  Role of autophagy in the pathogenesis of inflammatory bowel disease.

Authors:  Tomoya Iida; Kei Onodera; Hiroshi Nakase
Journal:  World J Gastroenterol       Date:  2017-03-21       Impact factor: 5.742

Review 2.  Inflammatory Bowel Disease Drugs: A Focus on Autophagy.

Authors:  Kirsty M Hooper; Peter G Barlow; Craig Stevens; Paul Henderson
Journal:  J Crohns Colitis       Date:  2016-07-05       Impact factor: 9.071

3.  Monitoring-Based Model for Personalizing the Clinical Process of Crohn's Disease.

Authors:  Alberto de Ramón-Fernández; Daniel Ruiz-Fernández; Diego Marcos-Jorquera; Virgilio Gilart-Iglesias; Víctor Vives-Boix
Journal:  Sensors (Basel)       Date:  2017-07-05       Impact factor: 3.576

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.